Summary and Key Highlights
Edited by Kara Grant
Moderated by Dr Maurie Markman, the panel included Dr Kevin Kalinsky from Emory University, Dr Michael Cecchini from Yale Cancer Center, and Dr Jacob Sands from Dana-Farber Cancer Institute. The webinar covered groundbreaking research and clinical trials that have the potential to transform cancer treatment protocols.
Key presentations included the ESOPEC trial, which compared perioperative FLOT chemotherapy with neoadjuvant chemoradiotherapy for resectable esophageal adenocarcinoma, and the CROWN trial, which evaluated lorlatinib vs crizotinib for first-line treatment of ALK-positive non–small cell lung cancer. Additionally, Dr Kalinsky shared insights on the latest targeted therapies for breast cancer, emphasizing the role of trastuzumab deruxtecan and CDK4/6 inhibitors. The NADINA trial was also highlighted for its innovative approach in comparing neoadjuvant nivolumab and ipilimumab with adjuvant nivolumab for stage III melanoma.
Key Takeaways:
- ESOPEC Trial Results:
- The ESOPEC trial demonstrated that perioperative FLOT chemotherapy significantly improves overall survival compared with chemoradiotherapy with the CROSS regimen for resectable esophageal adenocarcinoma.
- Median overall survival was 66 months with FLOT vs 37 months with CROSS, showing a clear advantage for FLOT in managing systemic disease.
- CROWN Trial Findings:
- The CROWN trial showed lorlatinib's superior efficacy over crizotinib in treating ALK-positive non–small cell lung cancer, with 60% of patients on lorlatinib experiencing ongoing disease control at 5 years.
- Lorlatinib also exhibited better CNS penetration, crucial for patients with brain metastases.
- Advancements in Breast Cancer Treatment:
- Trastuzumab deruxtecan is proving effective for HER2-low and HER2–ultra-low breast cancer, potentially moving earlier in the treatment timeline.
- The postMONARCH study highlighted the benefits of continuing CDK4/6 inhibitors like abemaciclib after progression on palbociclib, offering new options for hormone receptor–positive, HER2-negative metastatic breast cancer.
- NADINA Trial Insights:
- The NADINA trial revealed that neoadjuvant therapy with nivolumab and ipilimumab for stage III melanoma showed improved 1-year event-free survival rates (83% vs 57%) compared with adjuvant nivolumab.
- Depth of response to neoadjuvant treatment was a strong predictor for long-term outcomes, indicating the potential of earlier immunotherapy intervention.
Our Editors Also Recommend:
- ESOPEC: FLOT Bests CROSS in Resectable Esophageal Cancer
- 'Impressive' 5-Year Progression-Free Survival With Lorlatinib in ALK+ NSCLC
- American Society of Clinical Oncology (ASCO) 2024
Also from Medscape Masters:
- Are Multitumor Blood Tests More Hype Than Help?
- Should Patients Have Immediate Access to Cancer Test Results?
Next Medscape Masters Event:
"Revolutionizing Healthcare: Al-Driven Solutions"
REGISTER NOW >>